$22 Million Invested in Inimex Pharma
Gregory T. Huang6/2/08
Inimex Pharmaceuticals, based in Vancouver, BC, has announced that it has closed a $22 million Series B venture round, led by Morningside Venture Investments. Inimex is focused on discovering and developing new medicines based on selective modulation of the innate immune response. The funds will help the company conduct the first clinical trials of an innate defense regulator drug.
Gregory T. Huang is Xconomy's National IT Editor and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com, call him at 617-252-7323, or follow him on Twitter at @gthuang.
